Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

A Retraction to this article was published on 01 September 2003


Reports of spontaneous regressions of metastases and the demonstration of tumor-reactive cytotoxic T lymphocytes indicate the importance of the host's immune system in controlling the devastating course of metastatic renal cell carcinoma1,2,3. Recent research indicates that immunization with hybrids of tumor and antigen presenting cells results in protective immunity and rejection of established tumors in various rodent models4,5,6,7,8. Here, we present a hybrid cell vaccination study of 17 patients. Using electrofusion techniques5, we generated hybrids of autologous tumor and allogeneic dendritic cells that presented antigens expressed by the tumor in concert with the co-stimulating capabilities of dendritic cells. After vaccination, and with a mean follow-up time of 13 months, four patients completely rejected all metastatic tumor lesions, one presented a ‘mixed response’, and two had a tumor mass reduction of greater 50%. We also demonstrate induction of HLA-A2-restricted cytotoxic T cells reactive with the Muc1 tumor-associated antigen and recruitment of CD8+ lymphocytes into tumor challenge sites. Our data indicate that hybrid cell vaccination is a safe and effective therapy for renal cell carcinoma and may provide a broadly applicable strategy for other malignancies with unknown antigens.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Characterization of the hybrid cell vaccine.
Figure 2: Immunological response data.
Figure 3: Clinical response to hybrid cell vaccination.


  1. 1

    Jayson, G.C., Middleton, M., Lee, S.M., Ashcroft, L. & Thatcher, N. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br. J. Cancer 78, 366–369 (1998).

    CAS  Article  Google Scholar 

  2. 2

    Lokich, J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 20, 416– 418 (1997).

    CAS  Article  Google Scholar 

  3. 3

    Jantzer, P. & Schendel, D.J. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. 58, 3078–3086 (1998).

    CAS  Google Scholar 

  4. 4

    Guo, Y. et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263, 518– 520 (1994).

    CAS  Article  Google Scholar 

  5. 5

    Stuhler, G. & Walden, P. Recruitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol. Immunother 39, 342–345 (1994).

    CAS  Article  Google Scholar 

  6. 6

    Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558–561 ( 1997).

    CAS  Article  Google Scholar 

  7. 7

    Wang, J., Saffold, S., Cao, X., Krauss, J. & Chen, W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516–5524 ( 1998).

    CAS  Google Scholar 

  8. 8

    Gong, J. et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 6279– 6283 (1998).

    CAS  Article  Google Scholar 

  9. 9

    Kugler, A. et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. 82, 487–493 (1998).

    CAS  Article  Google Scholar 

  10. 10

    Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).

    CAS  Article  Google Scholar 

  11. 11

    Stuhler, G. et al. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl. Acad. Sci. USA 96, 1532–1535 (1999).

    CAS  Article  Google Scholar 

  12. 12

    Brossart, P. et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309–4317 ( 1999).

    CAS  Google Scholar 

  13. 13

    Brossart, P. et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732–736 ( 1998).

    CAS  Google Scholar 

  14. 14

    Fujita, K. et al. Expression of MUC1 mucins inversely correlate with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer 80, 301–308 (1999).

    CAS  Article  Google Scholar 

  15. 15

    Anichini, A., Mazzocchi, A., Fossati, G. & Parmiani, G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J. Immunol. 142, 3692– 3701 (1989).

    CAS  Google Scholar 

  16. 16

    Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 110– 1118 (1994).

    Article  Google Scholar 

Download references


The authors thank M. Striepe. The general support of the blood bank, departments of radiology and radiotherapy and the HLA laboratory of the University of Göttingen is acknowledged.

Author information



Corresponding authors

Correspondence to Gerhard A. Müller or Rolf-Hermann Ringert.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kugler, A., Stuhler, G., Walden, P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids. Nat Med 6, 332–336 (2000).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing